Printer Friendly

GNT Biotech & Medicals awards Chidamide sales and marketing rights to Taiwan Specialty Pharma.

M2 PHARMA-June 22, 2018-GNT Biotech & Medicals awards Chidamide sales and marketing rights to Taiwan Specialty Pharma

(C)2018 M2 COMMUNICATIONS

Taiwan-headquartered GNT Biotech & Medicals Co Ltd (GNTbm, TPEx Emerging: 7427) has awarded Taiwan sales and marketing rights for anticancer drug Chidamide to pharmaceutical distribution company, Taiwan Specialty Pharma Corp, it was reported yesterday.

The sales and marketing rights are awarded for two indications; hormone

receptor-positive, HER-2 negative late stage breast cancer in post-menopausal patients; and peripheral T-cell lymphoma. The licensing agreement includes upfront and milestone payments of up to NTD30m with royalties from sales to be awarded separately.

The company also announced that it had already started its Phase III clinical trial for Chidamide when administered together with exemestane (Aromasin), an aromatase inhibitor, for the treatment of late stage breast cancer after receiving approval in 2017 for the trial by the Taiwan Food and Drug Administration (TFDA). The trial in six medical centers in Taiwan is being conducted in collaboration with Chipscreen Biosciences Ltd, of Shenzhen, China, using the same clinical trial protocol as its Phase III trial for the same drug combination in China.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:9TAIW
Date:Jun 22, 2018
Words:196
Previous Article:Novo Nordisk reports success in two Semaglutide phase 3a trials.
Next Article:Unichem Pharmaceuticals names new president and chief executive officer - North America for Unichem Laboratories.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters